<DOC>
<DOCNO>EP-0635007</DOCNO> 
<TEXT>
<INVENTION-TITLE>
HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF TYPE II-DIABETES.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3142	A61K3142	A61K31423	A61K31423	A61K3144	A61K3144	A61K314402	A61K314402	A61K31495	A61K31495	A61K31496	A61K31496	A61K3150	A61K3150	A61K31505	A61K31505	A61K3154	A61K3154	A61P300	A61P308	A61P310	C07D21300	C07D21374	C07D23900	C07D23934	C07D23938	C07D23942	C07D26300	C07D26358	C07D41300	C07D41312	C07D41700	C07D41712	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61P	A61P	A61P	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61P3	A61P3	A61P3	C07D213	C07D213	C07D239	C07D239	C07D239	C07D239	C07D263	C07D263	C07D413	C07D413	C07D417	C07D417	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
A compound of the formula A
<
1
>
-X-(CH2)n-O-A
<
2
>
-A
<
3
>
-CO.R
<
2
>
 (I) or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein: A
<
1
>
 represents a substituted or unsubstituted aromatic heterocyclyl group; A
<
2
>
 represents a benzene ring having three optional substituents; A
<
3
>
 represents a moiety of formula -(CH2)m-CHR
<
1
>
- wherein R
<
1
>
 represents a halogen atom or a moiety of formula S(O)pA
<
4
>
 wherein A
<
4
>
 represents hydrogen, substituted or unsubstituted alkyl, aryl, aralkyl, alkylcarbonyl or an aromatic heterocyclyl group and p represents zero or an integer 1 or 2 and m represents zero or an integer in the range of from 1 to 5, or A
<
3
>
 represents a moiety of formula -CH=CR
<
1
>
- wherein R
<
1
>
 is as defined above; R
<
2
>
 represents OR
<
3
>
 wherein R
<
3
>
 represents hydrogen, alkyl, aryl or aralkyl, or R
<
2
>
 represents -NR
<
4
>
R
<
5
>
 wherein R
<
4
>
 and R
<
5
>
 each independently represent hydrogen or alkyl or R
<
4
>
 and R
<
5
>
 together with the nitrogen atom to which they are attached form a heterocyclic ring; X represents O, S or NR wherein R represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; and n represents an integer in the range of from 2 to 6; a process for the preparation of such a compound, a pharmaceutical composition comprising such a compound and the use of such a compound and composition in medicine.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<DESCRIPTION>
HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF TYPE-II DIABETESThis invention relates to certain novel compounds, to a process for preparing such compounds, to pharmaceutical compositions containing such compounds and to 5 the use of such compounds and compositions in medicine.European Patent Applications, Publication Numbers 0008203, 0139421, 0155845, 0177353, 0193256, 0207581, 0208420, 0306228 and International Patent Application Publication No. WO 9101337 relate to thiazolidinedione derivatives which are disclosed as having hypoglycaemic and hypolipidaemic activity. Chem. 0 Pharm. Bull 1982, 30 (10) 3580-3600 relates to certain thiazolidinedione derivatives having hypoglycaemic and hypolipidaemic activities. Chem. Pharm. Bull 1982, 30 (10) 3563 also relates to certain ethyl 2-chloro propionate derivatives having hypoglycaemic and hypolipidaemic activities.It has now surprisingly been discovered that certain novel α-thiocarbonyl and 5 α-halocarbonyl derivatives show good blood-glucose lowering activity and are therefore of potential use in the treatment and/or prophylaxis of hyperglycaemia and are of particular use in the treatment of Type II diabetes.These compounds are also indicated to be of potential use for the treatment and/or prophylaxis of other diseases including hyperlipidaemia, hypertension, 0 cardiovascular disease and certain eating disorders.Accordingly, the present invention provides a compound of formula (I):3 2-X (CH2)n— O A -A — CO.R(I)25 or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein:A*-- represents a substituted or unsubstituted aromatic heterocyclyl group;A* represents a benzene ring having three optional substituents;30 A*- represents a moiety of formula -(CH2)m-CHRl- wherein R*-- represents a halogen atom or a moiety of formula S(0)pA^ wherein A^ represents hydrogen, substituted or unsubstituted alkyl, aryl, aralkyl, alkylcarbonyl or an aromatic heterocyclyl group and p represents zero or an integer 1 or 2 and m represents zero or an integer in the range of from 1 to 5, or A** represents a moiety of formula -CH=CRl- wherein R* is as35 defined above;R2 represents OR wherein R***1 represents hydrogen, alkyl, aryl or aralkyl, or R2 represents-NR^R^ wherein R^ and R-- each independently represent hydrogen or 

alkyl or R^ and R-5 together with the nitrogen atom to which they are attached form a heterocyclic ring;X represents O, S or NR wherein R represents a hydrogen atom, an
</DESCRIPTION>
<CLAIMS>
Claims
1. A compound of formula (I) :
A — X (CH
2
)
n
 — O A
2
 A
3
 — CO.R
2
(I)
or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein: A* represents a substituted or unsubstituted aromatic heterocyclyl group; A
2
 represents a benzene ring having three optional substituents; A
3
 represents a moiety of formula -(CH2)
m
-CHRl- wherein R* represents a halogen atom or a moiety of formula S(O)pA
4
 wherein A
4
 represents hydrogen, substituted or unsubstituted alkyl, aryl, aralkyl, alkylcarbonyl or an aromatic heterocyclyl group and p represents zero or an integer 1 or 2 and m represents zero or an integer in the range of from 1 to 5, or A
3
 represents a moiety of formula -CH=CRl- wherein R* is as defined above;
R
2
 represents OR
3
 wherein R
3
 represents hydrogen, alkyl, aryl or aralkyl, or R
2
 represents-NR
4
R*5 wherein R
4
 and R-- each independently represent hydrogen or alkyl or R
4
 and R~- together with the nitrogen atom to which they are attached form a heterocyclic ring;
X represents O, S or NR wherein R represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; and _n represents an integer in the range of from 2 to 6.
2. A compound according to claim 1, wherein A* represents a moiety of formula (a), (b) or (c):
(a) (b) (c)
wherein:
R" and R ' each independently represents a hydrogen or halogen atom, an alkyl or alkoxy group or a substituted or unsubstituted aryl group or when R^ and R^ 


are each attached to adjacent carbon atoms, then R" and R-
7
 together with the carbon atoms to which they are attached form a benzene ring wherein each carbon atom represented by Rβ and R^ together may be substituted or unsubstituted; and in the moiety of formula (a) X-*- represents oxygen or sulphur.
3. A compound according to claim 1 or claim 2, wherein A
3
 represents - CH ^R
1
-.
4. A compound according to claim 1 or claim 2, wherein A
3
 represents -(CH
2
)
m
-CHRl.
5. A compound according to any one of claims 1 to 4, wherein Rl represents chlorine.
6. A compound according to any one of claims 1 to 4, wherein R*-- represents a moiety S(O)
p
 A
4
.
7. A compound according to claim 4, wherein A
4
 is iso propyl or phenyl.
8. A compound according to any one of claims 1 to 7, wherein R
2
 represents OR
3
 .
9. A compound according to any one of claims 1 to 8, wherein R
3
 represents hydrogen or alkyl.
10. A compound according to claim 1 selected from the list consisting of : methyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2- chloropropanoate; methyl 3-[4-[2-[N-(2-benzoxazolyl-N-methylamino]
ethoxy]phenyl]
-2- bromopropanoate; methyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2- iodopropanoate; methyl 3-[4-[2-[N-methyl-N-(2-pyridyl)amino]
ethoxy]phenyl]
-2-chloropropanoate; methyl 4-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2- chlorobutanoate;
3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2-chloropropanoic acid;
3-[4-[2-|^-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2-chloropropanamide; 



3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2-chloro-N,N- dimethylpropanamide; ethyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]
ethoxy]phenyl]
-2- fluoropropanoate; 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2-fluoropropanoic acid;
3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2-fluoropropanamide; ethyl (E)-3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]
ethoxy]-phenyl]
-2- fluoropropenoate; methyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2- (methylthio)propanoate;
3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2(methylthio)propanoic acid;
3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2-(methylthio)- propanamide; 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]
ethoxy]phenyl]
-2-mercaptopropanoic acid; methyl 2-(acetylthio)-3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]- ethoxy]
phenyl]propanoate;
3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2-(2- aminoethylthio)propanoic acid; methyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]
ethoxy]phenyl]
-2~
(phenylthio)propanoate; methyl 2-(benzenesulphonyl)-3-[4-[2-[N-(2-benzoxazolyl)-N- methylamino]ethoxy]
phenyl]propanoate; 2-(benzenesulphonyl)-3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]
ethoxy]- phenyl]
propanoic acid;
3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2-
(phenylthio)propanoic acid; methyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2-(4- methylphenylthio)propanoate;
3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2-(4- methylphenylthio)propanoic acid; methyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]
ethoxy]phenyl]
-2-(4- methoxyphenylthio)propanoate; 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2-(4- methoxyphenylthio)propanoic acid; methyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]
ethoxy]phenyl]
-2-(4- chlorophenylthio)ρropanoate; 


3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2-(4- chlorophenylthio)propanoic acid; methyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]
ethoxy]phenyl-2-(2- propylthio)propanoate; 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]
ethoxy]phenyl]
-2-(2- propylthio)propanoic acid;
3-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]
phenyl]-2-mercaptopropanoic acid; and methyl 3-[4-[2-[N-(2-benzoxazoIyl)-N-methylamino]
ethoxy]phenyl]
-2-(2- pyridylthio)propanoate; or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof.
11. A process for the preparation of a compound of formula (I), or a tautomeric form thereof, and/or a pharmaceutically acceptable salt thereof, and or a pharmaceutically acceptable hydrate thereof, which process comprises:
a) reacting a compound of formula (II):
a 2 3 2
R— A— A— CO.R (π)
wherein Rl, R
2
, A
2
 and A
3
 are as defined in relation to formula (I) and R
a
 is a moiety convertible to a moiety of formula (f):
Al-X-(CH
2
)
n
-0- (f)
wherein A*, X and n are as defined in relation to formula (I), with an appropriate reagent capable of converting R
a
 to the said moiety (f);
b) for the preparation of a compound of formula (I) , wherein A
3 '
 represents a moiety of formula - CH2)
m
-CHRl- wherein R* represents the above defined moiety S(O)pA
4
 and m is as defined in relation to formula (I), by reacting a compound of formula (Vπ):
A
1
 — X (CB,)
n
 — O — A
2
 (CH^ — CHL — CO — R 
2
(VII) 


wherein A***, A
2
, X, m and n are as defined in relation to formula (I), R^
2
 is as defined in relation to formula (IV) and L
2
 represents a leaving group, with a compound of the above defined formula (V);
c) for the preparation of a compound of formula (I) wherein A
3
 represents a moiety of formula (CH2) -CHRl- wherein R* represents a halogen atom, by deprotecting a compound of formula (VII) wherein R!
2
 is a protected form of R
2
 and L
2
 is halogen;
d) for the preparation of a compound of formula (I) wherein A
3
 represents a moiety of formula (CH2)
m
-CHR
1
- wherein R
1
 represents a halogen atom, by halogenating a compound of formula (VIII):
A —X (Cl-y 
n
 C—A
2
 — (CH,),, — CH, — CO— R 
2
 (VIII)
wherein A , A
2
, R--*
2
, X, m and n are as defined in relation to formula (VII), with an appropriate halogenating agent, and thereafter if required carrying out one or more of the following optional steps: (i) converting a compound of formula (I) into a further compound of formula (I); (ii) removing any protecting group; and
(iii) preparing a pharmaceutically acceptable salt of a compound of formula (I) and/or a pharmaceutically acceptable solvate thereof.
12. A process for the preparation of a compound of formula (I) or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, which process comprises reacting a compound of the above defined formula (XI), with a reagent capable of forming a moiety -A
3
'-CO-R
2
 from the -CHO group wherein A
3
' is -CH=CR
1
- wherein R
1
 is as described above and r is an integer 1 to 3; and thereafter if required carrying out one or more of the following optional steps: (i) reducing the compound so formed;
(ii) converting a compound of formula (I) into a further compound of formula (I); (iii) removing any protecting group; and (iv) preparing a pharmaceutically acceptable salt of a compound of formula (I) and/or a pharmaceutically acceptable solvate thereof. 


13. A process for preparing a compound of formula (I) wherein A
3
 represents a moiety of formula -(CH2)
m
-CHR*l- wherein Rl represents the above defined moiety S(0)pA
4
 and m is as defined in relation to formula (I),or a tautomeric form thereof, and or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, which process comprises hydrolysing a compound of formula (XV):
(XV) wherein A**-, A
2
, X, m and n are as defined in relation to formula (I) to provide a compound of formula (I) wherein Rl is SH and R
2
 is OH; and thereafter, if required, carrying out one or more of the following optional steps:
(i) converting a compound of formula (I) into a further compound of formula (I), in particular converting R-- is SH into another Rl and/or converting R
2
 is OH into another R
2
»
(ii) removing any protecting group; and
(iii) preparing a pharmaceutically acceptable salt of a compound of formula (I) and/or a pharmaceutically acceptable solvate thereof.
14. A pharmaceutical composition comprising a compound of the general formula (T), or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier therefor.
15. A compound of formula ®, or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and or a pharmaceutically acceptable solvate thereof, for use as an active therapeutic substance.
16. A compound of formula (T), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use in the treatment of and/or prophylaxis of hyperglycaemia, hyperlipidaemia, hypertension, cardiovascular disease and certain eating disorders.
17. A method for the treatment and/or prophylaxis of hyperglycaemia, hyperlipidaemia, hypertension, cardiovascular disease and eating disorders in a human or non-human mammal which comprises administering an effective, non-toxic, amount of a compound of the general formula (I), or a tautomeric form 


thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof to a human or non-human mammal in need thereof.
18. The use of a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of hyperglycaemia, hyperlipidaemia, hypertension, cardiovascular disease or certain eating disorders. 

</CLAIMS>
</TEXT>
</DOC>
